Factors Affecting the Price of Rezdiffra

The price of Rezdiffra is influenced by multiple factors. 

Factors Affecting the Price of Rezdiffra

Firstly, as the first approved treatment for MASH with liver fibrosis, its R&D costs are substantial. Developing a new drug involves years of research, clinical trials, and regulatory approvals, all of which contribute to a high price tag. Secondly, the market situation plays a role. With a large patient pool for MASH but no direct competitors initially, Madrigal Pharmaceuticals could set a relatively high price. 

However, as other potential treatments like Efruxifermin and Lanifibranor progress, competition may drive prices down. Thirdly, regulatory policies and insurance coverage impact the final price patients pay. If more insurers cover Rezdiffra, it may affect the net price the company can charge. Additionally, manufacturing costs, including raw materials and production processes for the 60mg, 80mg, and 100mg tablets, also factor into its pricing.